Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 58, Issue 3, 2004, Pages 673-680

  Serpe, L ^a   Catalano, M G ^a   Cavalli, R ^a   Ugazio, E ^a   Bosco, O ^a   Canaparo, R ^a   Muntoni, E ^a   Frairia, R ^a   Gasco, M R ^a   Eandi, M ^a   Zara, G P ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Cholesteryl butyrate; Doxorubicin; Paclitaxel; Sodium butyrate; Solid lipid nanoparticles

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; PACLITAXEL; SODIUM; SOLID LIPID NANOPARTICLE; TRYPAN BLUE;

ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG FORMULATION; DRUG SCREENING; FLOW CYTOMETRY; GROWTH CURVE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUTYRIC ACID; CELL SURVIVAL; CHOLESTEROL ESTERS; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HT29 CELLS; HUMANS; NANOSTRUCTURES;

EID: 4644268591     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2004.03.026     Document Type: Article

References (38)

1. Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug. Del. Rev. 54:2002;631-651
2. Ravi Kumar M.N.V. Nano and microparticles as controlled drug delivery devices. J. Pharm. Pharmaceut. Sci. 3:(2):2000;234-258
3. Gasco M.R. Solid lipid nanospheres from warm micro-emulsions. Pharm. Technol. Eur. 9:(11):1997;52-58
4. Cavalli R., Bargoni A., Podio V., Muntoni E., Zara G.P., Gasco M.R. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J. Pharm. Sci. 92:(5):2003;1085-1094
5. Gasco M.R. Solid lipid nanoparticles for drug delivery. Pharm. Technol. Eur. 13:2001;32-41
6. Santini V., Gozzini A., Scappini B., Grossi A., Rossi Ferrini P. Searching for the magic bullet against cancer: the butyrate saga. Leuk. Lymph. 42:(3):2001;275-289
7. McIntyre A., Gibson P.R., Young G.P. Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut. 34:(3):1993;386-391
8. Barnard J.A., Warwick G. rapidly induces growth inhibition and differentiation in HT-29 cells. Cell. Growth Differ. 4:(6):1993;495-501
9. WAF1 is required for butyrate mediated growth inhibition of human colon cancer cells. Proc. Natl Acad. Sci. 95:1998;6791-6796
10. Miyake H., Hara S., Arakawa S., Kamidono S., Hara I. Overexpression of Bcl-2 regulates sodium butyrate- and/or docetaxel-induced apoptosis in human bladder cancer cells both in vitro and in vivo. Int. J. Cancer. 93:(1):2001;26-32
11. Pouillart P.R. Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies. Life Sci. 63:(20):1998;1739-1760
12. Booser D.J., Hortobagyi G.N. Anthracycline antibiotics in cancer therapy: focus on drug resistance. Drugs. 47:1994;223-258
13. Nielsen D., Maare C., Skovsgaard T. Cellular resistance to anthracyclines. Gen. Pharmacol. 27:1996;251-255
14. Batist G., Ramakrishnan G., Rao C.S., Chandrasekharan A., Gutheil J., Guthrie T., Shah P., Khojasteh A., Nair M.K., Hoelzer K., Tkaczuk K., Park Y.C., Lee L.W. Cardiotoxicity and preserved antitumour efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 19:(5):2001;1444-1454
15. Spencer C.M., Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drug. 48:1994;794-847
16. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int. J. Pharm. 235:(1-2):2002;179-192
17. Horwitz S. Mechanism of action of taxol. Trend Pharmachol. Sci. 13:1992;134-135
18. Finley R.S. Patient care issue: the management of paclitaxel-related toxicities. Ann. Pharmacother. 28:1994;S27-S30
19. Zhang X., Burt H.M., Von Hoff D., Dexter D., Mangold G., Degen D., Oktaba A.M., Hunter W.L. An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel. Cancer Chemother. Pharmacol. 40:1997;81-86
20. Pellizzaro C., Coradini D., Morel S., Ugazio E., Gasco M.R., Daidone M.G. Cholesteryl butyrate in solid lipid nanoparticles as an alternative approach for butyric acid delivery. Anticancer Res. 19:(5B)):1999;3921-3926
21. Cavalli R., Caputo O., Gasco M.R. Solid lipospheres of doxorubicin and idarubicin. Int. J. Pharm. 89:1993;9-12
22. Cavalli R., Caputo O., Gasco M.R. Preparation and characterization of solid lipid nanoparticles incorporating paclitaxel. Eur. J. Pharm. Sci. 10:2000;305-309
23. Fundarò A., Cavalli R., Bargoni A., Vighetto D., Zara G.P., Gasco M.R. Stealth and non-stealth solid lipid nanoparticles (SLN) carrying doxorubicin: Pharmacokinetics and tissue distribution after I.V. administration to rats. Pharmacol. Res. 42:2000;337-343
24. Zara G.P., Cavalli R., Bargoni A., Fundarò A., Vighetto D., Gasco M.R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentration of stealth agent: pharmacokinetics and distribution in brain and other tissues. J. Drug. Target. 10:2002;327-335
25. Salomone B., Ponti R., Gasco M.R., Ugazio E., Quaglino P., Osella-Abate S., Bernengo M.G. In vitro effects of cholesteryl butyrate solid lipid nanoparticles as a butyric acid pro-drug on melanoma cells: evaluation of antiproliferative activity and apoptosis induction. Clin. Exp. Metastasis. 18:(8):2001;663-673
26. Miglietta A., Cavalli R., Bocca C., Gabriel L., Gasco M.R. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int. J. Pharm. 210:2000;61-67
27. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. 1:2002;287-299
28. Brown D.A., Malkin T., Maliphant G.K. An X-ray examination of long-chain alkyldihydrogen phosphates and dialkylhydrogen phosphates and their sodium salts. J. Chem. Soc. 1955;1584-1588
29. Duncan I.W., Culbreth P.H., Burtis C.A. Determination of free, total and esterified cholesterol by high-performance liquid chromatography. J. Chromatogr. 162:(3):1979;281-292
30. Koppel D.E. Analysis of macromolecular polydispersity in intensity correlation spectroscopy the method of cumulants. J. Chem. Phys. 57:1972;4814-4818
31. Massing U., Fuxius S. Liposomal formulations of anticancer drugs. Selectivity and effectiveness,. Drug Resist. Updat. 3:(3):2000;171-177
32. ®): PGLA nanoparticles containing vitamin E TPGS. J. Controll. Rel. 86:2003;33-48
33. Beck P., Kreuter J., Reszka R., Fichtner I. Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drug mitoxantrone in murine tumour models. J. Microencapsul. 10:1993;101-114
34. Verdun C., Brasseur F., Vranokx H., Couvreur P., Roland M. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nonoparticles. Cancer Chemother. Pharmacol. 26:1990;13-18
35. KB in HT-29 colon cancer cells. Cancer Chemother. Pharmacol. 49:(1):2002;27-34
36. Patnaik A., Rowinsky E.K., Villalona M.A., Hammond L.A., Britten C.D., Siu L.L., Goetz A., Felton S.A., Burton S., Valone F.H., Eckhardt S.G. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res. 8:(7):2002;2142-2148
37. Batova A., Shao L.E., Diccianni M.B., Yu A.L., Tanaka T., Rephaeli A., Nudelman A., Yu J. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood. 100:(9):2002;3319-3324
38. Rabizadeh E., Bairey O., Aviram A., Ben-Dror I., Shaklai M., Zimra Y. Doxorubicin and a butyric acid derivative effectively reduce levels of Bcl-2 protein in the cells of chronic lymphocytic leukemia patient. Eur. J. Haematol. 66:2001;263-271